Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Kineret for the treatment of patients with Cryopyrin-Associated Periodic Syndromes (CAPS).
Help employers find you! Check out all the jobs and post your resume.
